Corbus Pharmaceuticals Reports $35M Net Loss in Q2 2026, Increases R&D Spending

Corbus Pharmaceuticals Holdings, Inc. reported significant financial results for the second quarter of 2026, revealing a net loss of $35.0 million, compared to a net loss of $17.7 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $58.0 million, up from $34.6 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which surged to $31.2 million in Q2 2026, a 105% increase from $15.2 million in Q2 2025. Total operating expenses for the quarter reached $36.2 million, reflecting an 89% increase year-over-year.

The company's total current assets decreased to approximately $122.8 million as of June 30, 2026, down from $166.0 million at the end of 2025. This decline was primarily driven by a reduction in cash and investments, which fell to $23.4 million and $94.6 million, respectively. Corbus's accumulated deficit also widened to approximately $613.4 million, indicating ongoing challenges in achieving profitability. The company’s cash flow from operating activities showed a net outflow of $55.2 million for the first half of 2026, compared to $33.0 million in the same period of 2025.

Strategically, Corbus has made notable advancements in its clinical pipeline, particularly with its lead product candidates, CRB-701 and CRB-913. The company is actively conducting a Phase 1/2 clinical trial for CRB-701, an antibody drug conjugate targeting Nectin-4-expressing tumors, and has recently initiated a Phase 1b study for CRB-913, aimed at treating obesity. The company also made a $10.0 million milestone payment to CSPC Megalith Biopharmaceutical Co., Ltd. in April 2026, reflecting progress in its licensing agreement for CRB-701.

Operationally, Corbus has expanded its workforce, contributing to increased personnel-related costs, which rose to $5.2 million for the first half of 2026. The company has also engaged in an open market sale agreement, raising approximately $9.1 million from the sale of 894,044 shares of common stock during the first half of 2026. Looking ahead, Corbus anticipates continued operating losses as it advances its clinical programs and seeks additional financing to support its operations. The company expects its current cash and investments will be sufficient to meet its operational needs for at least the next twelve months, although it acknowledges the necessity of raising further capital to sustain its growth and development initiatives.